Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
COVID-19
Medication-based treatment
Methadone
Opioid use disorder
Overdose
Telehealth
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
08
11
2020
revised:
16
04
2021
accepted:
22
04
2021
pubmed:
8
6
2021
medline:
15
12
2021
entrez:
7
6
2021
Statut:
ppublish
Résumé
Due to the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration (SAMHSA) has relaxed restrictions on methadone treatment in the United States. There is concern that the relaxation may increase fatal overdose rates. This study examines opioid treatment program (OTP) changes to methadone treatment during COVID-19 and changes in fatal methadone-involved overdose rates in Connecticut. From July 8th to August 18th, 2020, we conducted a comprehensive state-wide survey of all eight OTPs that dispense methadone in Connecticut to examine programmatic changes during COVID-19. We also analyzed state-level data on confirmed accidental opioid-involved deaths to assess if relaxation of take-home dosing restrictions and in-person attendance requirements correlated with increased methadone-involved fatal overdose rates. OTPs reported implementing multiple changes to methadone treatment in response to the COVID-19 pandemic. The percent of patients receiving 28-day take-home doses increased from 0.1% to 16.8%, 14-day take-home doses increased from 14.2% to 26.8%, and the percent receiving one or no take-home doses decreased from 37.5% to 9.6%. Monthly or more frequent drug testing decreased from 15% to 4.6% and 75.2% of individual counseling for methadone patients transitioned to telehealth. However, changes to methadone treatment varied considerably by program. OTP providers said restrictions on methadone should be relaxed and increases in take-home dosing as well as telehealth should be continued in non-pandemic situations. Methadone-involved fatalities relative to other opioid-involved fatalities did not increase in Connecticut following changes in OTP practices. Connecticut OTPs relaxed methadone treatment requirements during COVID-19. Since relaxing restrictions on methadone treatment has not increased fatal overdoses, we recommend that the reductions in-person dosing and attendance requirements implemented during the COVID-19 pandemic should be continued and made permanent.
Sections du résumé
BACKGROUND
Due to the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration (SAMHSA) has relaxed restrictions on methadone treatment in the United States. There is concern that the relaxation may increase fatal overdose rates. This study examines opioid treatment program (OTP) changes to methadone treatment during COVID-19 and changes in fatal methadone-involved overdose rates in Connecticut.
METHODS
From July 8th to August 18th, 2020, we conducted a comprehensive state-wide survey of all eight OTPs that dispense methadone in Connecticut to examine programmatic changes during COVID-19. We also analyzed state-level data on confirmed accidental opioid-involved deaths to assess if relaxation of take-home dosing restrictions and in-person attendance requirements correlated with increased methadone-involved fatal overdose rates.
RESULTS
OTPs reported implementing multiple changes to methadone treatment in response to the COVID-19 pandemic. The percent of patients receiving 28-day take-home doses increased from 0.1% to 16.8%, 14-day take-home doses increased from 14.2% to 26.8%, and the percent receiving one or no take-home doses decreased from 37.5% to 9.6%. Monthly or more frequent drug testing decreased from 15% to 4.6% and 75.2% of individual counseling for methadone patients transitioned to telehealth. However, changes to methadone treatment varied considerably by program. OTP providers said restrictions on methadone should be relaxed and increases in take-home dosing as well as telehealth should be continued in non-pandemic situations. Methadone-involved fatalities relative to other opioid-involved fatalities did not increase in Connecticut following changes in OTP practices.
CONCLUSIONS
Connecticut OTPs relaxed methadone treatment requirements during COVID-19. Since relaxing restrictions on methadone treatment has not increased fatal overdoses, we recommend that the reductions in-person dosing and attendance requirements implemented during the COVID-19 pandemic should be continued and made permanent.
Identifiants
pubmed: 34098303
pii: S0740-5472(21)00175-6
doi: 10.1016/j.jsat.2021.108449
pmc: PMC9758251
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108449Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
J Subst Abuse Treat. 2006 Dec;31(4):385-93
pubmed: 17084792
Drug Alcohol Depend. 2016 Dec 01;169:117-127
pubmed: 27810654
Drug Alcohol Depend. 2020 Sep 1;214:108176
pubmed: 32717504
Soc Sci Med. 2008 Oct;67(7):1065-73
pubmed: 18640760
JAMA. 1965 Aug 23;193:646-50
pubmed: 14321530
Cochrane Database Syst Rev. 2017 Apr 27;4:CD011983
pubmed: 28447766
Int J Environ Res Public Health. 2009 Feb;6(2):787-97
pubmed: 19440415
Nat Med. 2020 Jun;26(6):819-820
pubmed: 32555514
Lancet. 2020 Apr 18;395(10232):1243-1244
pubmed: 32305087
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):483-9
pubmed: 21147192
J Addict Med. 2016 Mar-Apr;10(2):93-103
pubmed: 26808307
Clin Pharmacol Ther. 2008 Apr;83(4):644-7
pubmed: 18305456
JAMA. 2019 Jun 4;321(21):2071-2072
pubmed: 31046072
Lancet Public Health. 2020 Apr;5(4):e186-e187
pubmed: 32171054
Ann Intern Med. 2020 Jul 7;173(1):59-60
pubmed: 32240291
JAMA. 2019 Dec 17;322(23):2340-2342
pubmed: 31846008
Br J Clin Pharmacol. 2014 Feb;77(2):253-63
pubmed: 23210630
Subst Abus. 2020;41(2):147-149
pubmed: 32314951
J Addict Dis. 2009;28(1):39-52
pubmed: 19197594
Am J Forensic Med Pathol. 2000 Dec;21(4):359-61
pubmed: 11111797
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110070
pubmed: 32800868
Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S3-11
pubmed: 12738346
Harm Reduct J. 2020 May 6;17(1):26
pubmed: 32375887
J Subst Abuse Treat. 2012 Apr;42(3):239-46
pubmed: 21943812
Ann Intern Med. 2020 Jul 7;173(1):57-58
pubmed: 32240283
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Drug Alcohol Depend. 2011 Sep 1;117(2-3):170-5
pubmed: 21310552
Lancet. 2021 Mar 20;397(10279):1139-1150
pubmed: 33617769
J Urban Health. 2020 Aug;97(4):448-456
pubmed: 32720298
Ann Intern Med. 2020 Jul 7;173(1):61-62
pubmed: 32240293
Addiction. 2003 Jul;98(7):995-1002
pubmed: 12814505
JAMA. 2005 Jan 19;293(3):297-8
pubmed: 15657321
Addiction. 2000 Mar;95(3):393-406
pubmed: 10795360
Health Aff (Millwood). 2019 Feb;38(2):287-294
pubmed: 30715966
Drug Alcohol Depend. 2020 Jul 1;212:108047
pubmed: 32447172
Ann N Y Acad Sci. 2000;909:186-216
pubmed: 10911931
NCHS Data Brief. 2020 Jan;(356):1-8
pubmed: 32487285
Am J Public Health. 1998 Jan;88(1):34-9
pubmed: 9584030